UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): August 3,
2021
MONOPAR THERAPEUTICS INC.
(Exact name of registrant as specified in its
charter)
Delaware
|
|
001-39070
|
|
32-0463781
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
1000 Skokie Blvd.,
Suite 350, Wilmette, IL 60091
|
|
60091
|
(Address of principal executive
offices)
|
|
(Zip Code)
|
(847) 388-0349
Registrant’s
telephone number, including area code
N/A
(Former
name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value
|
|
MNPR
|
|
The Nasdaq Stock Market LLC
(Nasdaq Capital Market)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
☐ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☒
Item 7.01
Regulation FD Disclosure
On
August 3, 2021, Monopar Therapeutics Inc. issued a press release
announcing clearance from the US Food and Drug Administration to
proceed under its IND with an open-label Phase 1b dose-escalation
trial evaluating camsirubicin plus growth factor support
(pegfilgrastim) in patients with advanced soft tissue
sarcoma.
The
press release is furnished as Exhibit 99.1 to this report and
incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits
Exhibit
No.
|
|
Description |
|
|
Press Release Dated August 3,
2021 |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Monopar Therapeutics Inc.
|
|
|
|
|
|
Date:
August 3, 2021
|
By:
|
/s/
Kim R. Tsuchimoto
|
|
|
|
Name:
Kim R. Tsuchimoto
|
|
|
|
Title:
Chief Financial Officer, Secretary and
Treasurer
|
|